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Summary
Cancer is one of the leading causes of death in the world. Current therapies are
rnainly focusing on eliminating the rapidly growing tumor cells by surgery,
radiotherapy and/or chemotherapy. The major disadvantages of these approaches
are the poor accessibility of tumor cells, development of drug resistance, and
toxicity of drugs towards non-tumor cells. Therefore, new therapeutic strategies
need to be develooed.
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Figure I. Schematic presentation ol' the importonce of angiogenesis 
.f'or tumor grov,th.
Angiogenesis lrans/brms a,small, relatively harmless, cluster oJ tumor cells (knotyn as an
ín sittt tttmor') into a large lumor mass that can negativellt inflttence organ 
-/unctbn and
can metastasize to oÍher orguns. Dnrgs that inter/ère with angiogenesis or othenri,se
block the tuntor hlood supply can reduce the size of a Íumor. (Modi/ied /rom Folkmon,
I996 ).
In the early 1970's, it was recognized that the fonnation of new blood vessels
from pre-existing ones, also known as angiogenesis. ts an important process in
tumor growth (Fig. l). Growth and survival of tumor cells depend on oxygen and
nutrients supplied by the blood. As a consequence, the size of a tumor is restricted
to a few cubic millirneters without the recruitment of new blood vessels. For a
long time, it was thought that angiogenesis only occurs by sprouting of pre-
existing vessels. Recently, it has become apparent that circulating endothelial
progenitors, mobilized from the bone marrow, can contribute to neovessel
fbrmation as well. Since, in general, a large number of tumor cells depends on a
small number of blood vessels Íbr their growth and survival, inhibition of the
blood supply is an effective approach to destroy solid tumors. It should be
rnentioned here that angiogenesis is also critically involved in chronic
int'larnmation, and would, thereÍbre, be an attractive target in the treatment of
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- Strmmary', general cli,scus,sion and pet'spectiye,e -
chronic inflammatory diseases as well. However, in this thesis we Íbcus on tumor
angiogenesis a  targct Íor our strategies.
Endothelial cells are prorninent players in angiogenesis. This, together u'ith the
fact that endothelial cells are easily accessible and genetically stable, merkes them
attractive targets for therapeutic intervention. Furthermore, inhibition of
angiogenesis is, theoretically, independent of the type and location of a tumor,
rnaking anti-angiogenic therapies suitable for many tumors. DrLrg targeting
approaches are a valuable tool for selective delivery of drugs that eitlier do not
reach the target cells sufficiently or are too toxic to non-target cells when applied
systemically.
For successful drug targeting to angiogenesis-associated blood vessels.
angiogenic endothelial cells need to be discriminated from the normal quiescent
endothelium. In the past dc-cade, using cellular and molecular biological
approaches. many receptors, e.g.. cr,p3, VEGFR, MMP-2/-9, Endoglin (CDl05),
and Aniinopeptidase N (CDl3), have been identiÍled to be upregulated on tumor
endothelial cells. In theory, these receptors can be explored as target epitopes for
drug targeting purposes. Besides epitopes on endothelial cells, the ED-B domain
of fibronectin (B-FN), a componeut of the extracellular matrix. lras been described
as a target epitope fbr tumor vasculature targeting. One of the most-studied target
epitopes on angiogenic neovasculature is the u,B3 integrin. This integrin mediates
cell adhesion to extracellular natrix proteins by recognizing an Arg-Gly-Asp
(RGD) sequence. RCD peptides with a constrained configuration have a high
affinity Íbr u"B3 integrin, and can be used to target drugs to angiogenic endothelial
cel  Is.
Several approaches exploiting different target epitopes were investigated for
their potential to interÍère with the neovascular endothelium. For instance, toxic
drugs (Arap et al., 19981' Arora et al.,1999), apoptosis-inducing agents (Ellerby e/
ul., 1999). cytokines (Carnernolla et ol., 2002; Curnis et al., 2000), and
t lrerapeut ic genes (Hood el  a| . ,2002) were del ivered ( in)to tumor endothel ial
cells, leading to reduced turnor growth. Furthermore, angiogenesis and tumor
growth were inhibited upon occlusion of blood vessels by targeting coagulation
factors to tumor vasculature (Huang et al . ,1997, Ni lsson et a| . .2001 Ran et al . .
1998). Recently. imniune eÍïector cells u'ere targeted to angiogenic blood vessels.
leading to lysis of tumor endothelial cells and suppression of tumor growth
(Niederman et al.. 2002).
The research described in this thesis aimed at the development of RGD-
containing protein conjugates fbr the delivery of pharmacologically active agents
or immune eÍïector cells to ouB3 on tumor vasculature. Chapter I summarizes the
current status and development of er-rdothelial cell-specific drug targeting
strategies fbr the treatment of cancer and chronic inflammation. The role of
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endothelium in normal physiology, cancer and chronic inflamrnatory diseases, the
development of macromolecular drug carriers, drugs of interest for interfering
with endothelial cell (dys)Íunction, and in vitro and in uivo experimental
approaches to study (intracellular) drug delivery (in)to endothelial cells are
reviewed.
In Chapter 2 the aim of the research described in this thesis is presented.
Chapter 3 and Chapter 4 describe the synthesis and characterization of
multivalent RGD-rnodified proteins under development for drug targeting to cr,B3
on angiogenic endothelium. We chemically conjugated RGD (cRGDfK) and
mismatched control RAD peptides (cRADfK) to a human antibody backbone
(HuMab) as a model protein. The peptide:protein ratio was varied in the syntheses
to obtain conjugates with different peptide load. We demonstrated that upon
conjugation, the resulting RGDpep-HuMab conjugates peciÍically bound to both
murine (H5V) and human endothelial cells (HUVEC), whereas the control
RADpep-HuMab conjugate did not. Moreover, RGDpep-HuMab conjugates
completely inhibited the adhesion of HUVEC to oup: ligand vitronectin,
indicating that the binding was ouBj specific. The binding of RGDpep-HuMab
conjugates was increased in the presence of divalent cations, which is in
agreement with the Íact that interaction of o,,Bj with a ligand is dependent on
divalent cations (Legler et al.. 2001 ). Furthennore, we demonstrated that
multivalent RGDpep-HuMab conjugates bind to endothelial cells with
dramatically increased avidity. The affinity of the conjugate with the highest
peptide load was increased over 1000-fbld as compared to the uncoupled peptide.
Most likely, clustering of integrins by multivalent interaction of RGDpep-HuMab
conjugates leads to an increase in avidity (van Kooyk and Figdor, 2000). From
these data, we concluded that RGD-modified proteins can be further exploited for
selective targeting of drugs or effector cells to cr,,B3 on tumor vasculature.
In addition, internalization of radiolabeled RGD-rnodified proteins into
primary human endothelial cells was investigated (Chapter 4). RGDpep-
HuMab(lV), the conjugate with 23 peptides coupled per protein backbone, was
internalized by HUVEC and degraded via the lysosomal pathway. This implies
that RGD-modified proteins can be exploited for intracellular delivery of drugs
into cr.\,Br-expressing angiogenic endothelial cells. Although we hereby
demonstrated internalization of RGD-modified proteins into primary endothelial
cells rn viíro, the endocytotic capacity of angiogenic endothelial cells ín vivo
remains to be established.
In Chapter 5, the biodistribution and pharmacokinetics of RGD-modified
proteins in mice bearing subcutaneous Bl6.F10 melanoma tumors are presented.
The RGDpep-HuMab(lV) conjugate localized in the tumor specifically at the
endothelium after intravenous administration in tumor-bearins mice. Additionallv.
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- Summaty, general discussion and per.spectives -
RGDpep-HuMab(IV) was taken up by liver and spleen, probably by cr,pr-
expressing macrophages. The halÊlife of RGDpep-HuMab(lV) was prolonged as
compared to the half-life of RGD peptides reported in literature (t12:90 min and
< l0 min, respectively). This is an advantage in terms of targeting potential, since
the target cells are exposed to the conjugate for a longer time period.
Retargeting of cytotoxic T lymphocytes (CTLs) in order to specifically lyse
tumor cells has been extensively studied as an approach to treat cancer. However,
at present, this approach as not yet been successful. due to, among others, lack of
infiltration of CTLs in the tumor tissue and the large number of target cells that
needs to be killed. Retargeting of CTLs to tumor endothelial cells could be an
alternative approach. Not only will accessibility of the target cells be much better
compared to tumor cell retargeting strategies, but also endothelial cell-directed
immunotherapy will have an ampliÍ'ïcation effect, i.e.. less target cells have to be
destroyed to induce a strong anti-turnor esponse.
By conjugating RGD peptides to a monoclonal anti-CD3 antibody, we
prepared biÍunctional conjugates that bound to both CD3 on CTLs and o,F: on
tumor endothelial cells (Chapter 6). Furthermore, both RADpep- and RGDpep-
anti-CD3 conjugates were able to activate CTLs via CD3 binding. We
demonstrated that RGDpep-anti-CD3 conjugates were able to selectively redirect
the cytolytic capacity of CTLs towards HUVEC, whereas RADpep-anti-CD3
conjugates had no effect.
Taken together, coupling of monocyclic RGD peptides to a protein backbone
results in a multivalent macromolecular conjugate with an increased avidity for
auB3, improved pharmacokinetic behaviour, and the ability to specifically localize
at the tumor vasculature in vivo.ln addition, RGD-modified anti-CD3 antibodies
were able to cross-link immune effector cells with angiogenic endothelium and
induce specific lysis of c{,up3-expressing e dothelial cells in vitro. Based on this
concept, dntgs can be attached to the protein backbone or proteins rvith functional
activity on their own can be conjugated with RGD peptides to be targeted to the
tumor endothelium. Future studies using animal tumor models will have to reveal
the potential of RGD-modified macromolecular conjugates to induce anti-tumor
effects mediated via the vascular component.
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